

August 8, 2016

Equity Research

WELLS
FARGO

SECURITIES

Good For the Goose, Less For the Gander

New Rules of Engagement Set To Benefit MO and RAI

- **The August 8th “Freeze Date” Has Arrived! E-Cig/Vapor Industry Chafes At The New Rules of Engagement That Stifle Innovation – MO/RAI Actively “Engage” With the FDA Supporting Hope for Potential Industry-Friendly Changes** – While the final deeming e-cig regulation brings much needed structure and oversight to the e-cig/vapor category, **there is little doubt that the cost and complexity of compliance overwhelmingly favor big tobacco (the goose) at the expense of smaller, less well-funded players (the gander).** MO and RAI are, as expected, ahead of the game with RAI having launched “numerous” VUSE formats ahead of today’s Aug 8 deadline - the date after which no new products can be sold without FDA authorization, and MO persuading the FDA to not enforce a descriptor ban on its Black & Mild cigar brand, demonstrating its command of the issues and legal acumen. As industry leaders, MO & RAI are actively engaged with the FDA on a number of critical issues that could have longstanding effects on innovation, the promotion of healthy competition, and ultimately consumer choice. **Bottom line – Both MO & RAI appear well prepared to comply with the FDA’s deeming regs, if not benefit from potential category consolidation. That said, the companies are rightfully taking the longer view as they actively work with the FDA to ensure a rich environment for innovation and healthy competition. As such, we reiterate our Overweight sector rating and Outperform ratings on RAI given its strong VUSE positioning, and MO given its opportunity with IQOS.**
- **FDA “Open” to Hearing Top Industry Concerns – Stifles Innovation, Restrictive Predicate Date, Disregards ‘Continuum of Risk’ Principle** – In addition to multiple lawsuits and legislative action pending, we believe MO & RAI lend considerable weight to current stakeholder discussions with the FDA to rethink some of the more strident areas of the regulation. We were pleased to hear both companies reporting that the FDA is “open to listening,” “not immune,” and “more straightforward” than it would appear. As such, we are increasingly optimistic that the ultimate outcome won’t be as deleterious to the category or as burdensome as we originally feared.
- **Further Implications of Deeming Regs: (1) We expect to see a continued shift in consumption of e-cigs/vapor back to combustible cigs as e-cig choices become more limited -- a net ‘win’ for big tobacco. This has continued to baffle us given the FDA’s public health priorities. (2) We expect further e-cig/vapor consolidation and, as a result, manufacturers’ pricing power and retail leverage to increase with MO and RAI best positioned given their scale and capabilities. (3) We expect increased, but manageable, timing risk for MO to be able to commercialize IQOS by late FY17/early FY18 assuming its premarket tobacco application (PMTA) is approved given PM & MO’s active dialogue with the FDA.**
- **As Is, Deeming Regs Are A Clear ‘Win’ For Big Tobacco, Not Necessarily Public Health** – Our main concern remains that the final deeming e-cig regs will realistically stifle innovation, which could dramatically slow industry growth by dis-incentivizing consumer conversion from combustible cigs to e-cigs. This ultimately has a net negative impact on public health, which is **clearly in direct opposition to the FDA’s goal.** However, we have reason to be more optimistic given actions being taken by both MO & RAI to soften the current limitations of the deeming regs on innovation.

Tobacco

Bonnie Herzog, Senior Analyst
(212) 214-5051
bonnie.herzog@wellsfargo.com
Patty Kanada, CFA, Associate Analyst
(212) 214-5029
patty.kanada@wellsfargo.com
Adam Scott, Associate Analyst
(212) 214-8064
adam.scott@wellsfargo.com

Please see page 7 for rating definitions, important disclosures and required analyst certifications

All estimates/forecasts are as of 08/08/16 unless otherwise stated.

Wells Fargo Securities, LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of the report and investors should consider this report as only a single factor in making their investment decision.

Together we'll go far



New Rules of Engagement

Since the FDA issued in May its final deeming rule to extend regulatory oversight to all tobacco products, tobacco manufacturers have been under enormous pressure to: **(1)** get new products out the door into market or test market ahead of today's **August 8** effective date -- the date after which no new products can be sold without FDA authorization, and **(2)** get started on preparing either Substantial Equivalence (SE) exemption requests or Premarket Tobacco Applications (PMTA), which start to become due in 2018, to keep products in the market (see our Deeming Regs application timeline chart below). Given the Aug 8 effective date has arrived and that MO and RAI have both reported Q2 results, we thought an update was in order on where the industry and MO and RAI, in particular, stand with regard to the FDA's new "rules of engagement."

First off, we believe the sweep of the new regulation has been a real blow to the broader vapor industry, particularly smaller, less well-funded players, and innovation more broadly, given the costly and time consuming requirements and because innovation will likely be stifled. While perhaps not hugely evident yet, we believe many small industry players will be forced out of business as a result which has been foreshadowed by several announced leadership departures at many companies and industry/trade groups. Those left standing, may seek "white knights" or consolidation in an attempt to build a stronger, more survivable competitive platform. **Large, well-funded manufacturers such as MO (MO, 1, \$66.22) and RAI (RAI, 1, \$49.22), however, are doing well** (no surprise). Their key vapor brands (RAI's VUSE, MO's MarkTen XL) continue to receive critical investment and marketing/distribution support and are among the few vapor brands thriving, which is evident in recent Nielsen measured channel data and feedback in our "Tobacco Talk" retailer survey (see charts below).

RAI Appears Well Prepared; We Expect VUSE To Be A Primary Beneficiary of Deeming Regs

RAI continues to invest behind its VUSE platform and has reportedly launched "numerous" formats ahead of today's Aug 8 deadline to ensure that it will "have choices to work with the [FDA] on potentially rolling those out" in compliance with the final deeming regulations. In the meantime, VUSE continues to grow with volume "significantly up." Suffice it to say, RAI is "very pleased" with the brand and we see no reason it won't continue to succeed in the new regulatory environment, if not benefit from it.

MO Equally Prepared, Working on FDA Compliance, Proceeding with "Financial Discipline"

MarkTen XL continues to show "encouraging" progress with retailers reporting a second round of "heavy" couponing helping to build trial awareness and sales. Nu Mark's distribution of the brand at retail now represents ~50% of e-vapor category volume with "very good marketplace response," according to MO. While feedback from our "Tobacco Talk" retailer contacts and Nielsen data corroborate the brand's strong relative performance (see charts below), it is still early days for the XL line extension, which is driving recent gains, and we expect MO to maintain financial discipline as it stages its rollout. On the FDA front, MO likewise reports itself to be "well-prepared" to meet requirements under the new regulations. Both Nu Mark and Middleton (MO's cigar business) are working on compliance and are actively engaging with FDA regulators and "other stakeholders" to advocate for changes to the regs.


MO/RAI Remain Actively "Engaged" With the FDA; Suggests Change Could Be Afoot

Both MO & RAI report active engagement with the FDA on a number of fronts, including: **(1)** clarification of the process, **(2)** preventing the new regs from stifling innovation, **(3)** amending the 2007 predicate date given that most vapor products currently sold "basically came into the marketplace after 2007," and **(4)** ensuring that the regs stay true to the underlying 'continuum of risk' principle espoused by FDA Tobacco Director Mitch Zeller: "Anyone who would ponder the endgame must acknowledge that the continuum of risk exists and pursue strategies that are designed to drive consumers from the most deadly and dangerous to the least harmful forms of nicotine delivery."

Short of lawsuits (the FDA is reportedly already facing many) and legislative action (namely, the Cole-Bishop Amendment) prevailing, we believe MO & RAI lend considerable weight to current stakeholder discussions with the FDA to rethink some of the more strident areas of the regulation. MO says it has found the FDA to be "open to listening to reasonable arguments" and "not immune from listening to different points of view and coming to some reasoned judgment." On a positive note, RAI reports "a lot of signaling" that suggests the FDA process will be "more straightforward" than previously feared. MO, for its part, has successfully persuaded the FDA to not enforce a descriptor ban on its Black & Mild cigar brand (The FDA had purported that deeming regs' ban on cigarettes from using the terms "mild," "light" and "low" on product labels extended to cigars). We believe the implications will be far-reaching in that the matter demonstrated MO's clear command of the issues, influence and legal acumen relative to the FDA. **Given MO & RAI's interest in growing the industry, we expect they will play an active role in any regulatory reshaping that occurs.**


No Sign of Speedbumps for iQOS Commercialization

We were pleased to hear from MO that plans are on track for PM (PM, 1, \$99.14) to submit its FDA applications for pre-market authorization (PMTA) and a modified-risk tobacco product (MRTP) designation for iQOS by year end with “excellent progress” being made on commercialization strategies. As such, we continue to expect iQOS to hit store shelves as early as late 2017/early 2018 without a health claim assuming the application is filed in late 3Q16/early 4Q16. As such, we continue to expect iQOS to add \$10/shr to MO, which we believe is not entirely captured in MO’s current share price. To briefly reiterate our conclusions from our March 9, 2016 note, “PM – Changing the World One Smoker at a Time,” we believe: **(1)** iQOS will accelerate MO’s operating profits by 260bps to a 9% CAGR and MO’s EPS by 250bps to a 10% CAGR in the next decade; **(2)** iQOS could displace up to 30% of the U.S. combustible cig industry by 2025, increase smoking prevalence and accelerate the premiumization of the overall market; and **(3)** iQOS could add incremental value of \$10 per share for MO, which we believe is being underestimated.



Source: Nielsen Total US xAOC Including Convenience Database and Wells Fargo Securities, LLC “Tobacco Talk” surveys

Tobacco




Source: Nielsen Total US xAOC Including Convenience Database and Wells Fargo Securities, LLC “Tobacco Talk” surveys

Retailers Increasingly Optimistic About Reduced-Risk Products (RRPs)

In the meantime, retailer sentiment on the vapor category and the future of RRP continues to improve. In general, retailers see deeming regs leading to further consolidation within the industry which should weed out non-viable players and aid category management. They also see the regs putting more power in the hands of the few (i.e., well-funded, big tobacco), which could leave retailers at a disadvantage in terms of contract negotiation and, ultimately, margin/profits.

While MO holds the advantage, we believe, on RRP with PM in its corner, the challenge, we think, for RAI is to articulate where it sees itself on the spectrum of broader RRP development and how it’s positioning itself to

be able to fully participate in light of strong science-backed advances by PM (iQOS) and the eventual commercialization of iQOS in the U.S. by MO.



What Are You (Retailers) Most Excited or Concerned About With Regard to the E-Cig/Vapor/Reduced-Risk Products (RRP) Category?
"New POGs with space for most companies. Natural premium products, consumers trading up to premium products at higher penny profit. Consolidation of the vape category."
"If the FDA ever gets through with their regulations, will be left with Vuse, Mark Ten, Blu & Logic which will be a good thing."
"The industry does not go anywhere since you actually have to have an addictive product which the majority accepts and the majors have done everything in their powers to make sure the price of those products is way too expensive so as to maintain their margin on cigarettes, so acceptance will never happen."
"Should see lift in a couple of years with technological advancement."
"Tobacco sales are still 75% of sales. Wholesalers must find other items to replace this. Like foodservice."
"Concerned about the unknown. Concerned with decrease in margin and profits if the category is dominated by major players."
"My only excitement is hopeful governmental procrastination and gridlock!!"
"Swedish Match has a winner coming out with ZYN. Watch it take off. I was able to try it and it is good stuff. No Surgeon General's warning. Once something is labeled Modified or reduced, it will explode."
"I would like to see regulatory step it up and reduce the number of entities selling e-cig, vape, etc."
"Higher sales are possible now, whereas before they were just a dream."
"Finally getting some regulation in the E-Cig/Vapor categories is a plus. It may not be exactly what everyone wants but getting the regulation and 'now you know' behind us will help. I anticipate some type of Federal taxing on that category next."
"SET increases more likely than not RJR. Going to attempt to exert more power on fixtures to enforce higher of chain share of space or market share of space whichever is higher thereby potentially crowding out ITG, LVB, NAS, KMM, etc. Litigation possible."
"Excited about the uses for vape other than just nicotine delivery. Concerned about government regulations based on ""good intentions"" instead of science."
"More clarity in the business."
"Regulations will kill innovation."
"Consumers have options and margins which is good."
"No excitement just hoping that any declines are slow and is offset by growth in Smokeless."
"Believe cigarettes are returning back to normal rates of decline. We remain concerned and believe we will see further declines in ITG Brands."
"Implications of FDA regs."
"I'm excited that the RJR and Altria folks are still working to provide a viable alternative to regular cigarettes. I hope we see something break in the next 6 months."
"A lot of ex tobacco consumers want to return to a reduced risk environment."
"Nothing. Deeming regs have killed what hope was there."

Source: Wells Fargo Securities, LLC "Tobacco Talk" Retailer Surveys

Clarity on Timing & Review of Applications to the FDA - In terms of timing and process, there are three essential 'pathways' to obtain FDA approval with the official 'clock' starting today, the effective date – the first two being not terribly viable options. Manufacturers can file for: (1) a substantial equivalence (SE) exemption, (2) an SE determination, or (3) a Premarket Tobacco Application (PMTA). The first two are the least burdensome pathways, but are for all intents and purposes not viable for most companies as they require new products to be based on a "predicate" product that is substantially equivalent to the new product having been on the market before February 15, 2007 (the "predicate date" or "grandfather" date). The problem is that there were very few e-cig/vapor products on the market before February 15, 2007. We count only a handful,

Tobacco

including RAI's original heat-not-burn *Eclipse* product (launched in the 1990s), Brown & Williamson's *Advance Lights* (test marketed in 2001), and Vector Tobacco's *Omni* brand (launched in the early 2000's). Furthermore, we find it interesting that February 15, 2007 was set as the predicate date as it was originally set as the predicate date for the Tobacco Control Act of 2009. **Bottom line – Whether intended to or not, we believe the FDA has effectively (even if inadvertently) engaged in a form of protectionism that favors big tobacco/combustible cigs, shielding the top players from incursions by smaller players and thereby stifling much-needed competition.**

Key Deeming Reg Compliance Dates					
Month	Industry Deadlines*	Event/Filing Pathway	Meaning	Ultimate Deadline For FDA Decision	Our Comment
0	August 8, 2016	Effective date	Companies are prohibited from (1) introducing new products into the market and (2) making changes to existing products without formal FDA approval	--	Largely viewed to be an arbitrary date. But after this date, not even small changes to products will be allowed. For example, not even a battery upgrade that would improve the safety of the product would be allowed
12	August 8, 2017	Substantial Equivalence (SE) <u>exemption</u> filing deadline	Companies may request to be exempt from the FDA process if they had a "predicate" product on the market prior to Feb 15, 2007 (the "predicate date" or "grandfather" date) that is <u>for all intents and purposes the same</u> ("substantially equivalent") as the product under consideration	August 8, 2018	One of two "least burdensome pathways" to FDA approval, but won't apply to the vast majority of manufacturers as there were very few vapor products in existence in 2007.
18	February 8, 2018	Substantial Equivalence (SE) <u>application</u> filing deadline	Companies filing for this determination would need to show that their new products are <u>similar</u> to a predicate product on the market in 2007	February 8, 2019	Also a least burdensome pathway, but again very few companies will meet this threshold -- We can think of just a handful, including (1) RAI's original heat-not-burn <i>Eclipse</i> product (marketed in the 1990s), (2) Brown & Williamson's <i>Advance Lights</i> , and (3) Vector Tobacco's <i>Omni</i> brand
24	August 8, 2018	Premarket Tobacco Application (PMTA) application filing deadline	Full, new product application	August 8, 2019	Expected to be prohibitively expensive for all but the most deep-pocketed manufacturers, i.e., big tobacco
*The FDA has 12-mos from each filing to approve or deny applications, making August 8, 2019 the ultimate 'deadline' in this initial round					

Source: FDA, Wells Fargo Securities, LLC

Rating Basis Information:


MO Thesis: We believe Altria is achieving a better balance between stabilizing Marlboro market share and growing profitably. We see further upside from strong pricing trends and potential of vapor that isn't currently reflected in the stock.

PM Thesis: We expect PM to outperform over the long term given its (1) superior and re-invigorated Marlboro brand franchise, (2) its industry-leading, diverse brand portfolio, and (3) its impressive ROIC and improving economic profit. PM has emerged in a class of its own and we believe it is poised for further growth.

RAI Thesis: We believe RAI has transformed itself into a more focused, total tobacco company, driven by innovation and a methodical approach to driving sustainable growth. We believe the stock has further upside potential given several growth drivers.

Required Disclosures

Altria Group, Inc. (MO) 3-yr. Price Performance



Date	Published Price (\$)	Rating Code	Val. Rng. Low	Val. Rng. High	Close Price (\$)
8/6/2013		Herzog			
8/6/2013	NA	1	39.00	41.00	35.40
12/3/2013	37.23	1	40.00	42.00	37.17
1/27/2014	35.35	1	39.00	41.00	36.83
5/19/2014	40.69	2	41.00	43.00	40.21
10/30/2014	47.55	2	46.00	48.00	47.50
1/20/2015	53.05	1	56.00	58.00	53.83
1/30/2015	53.10	1	59.00	61.00	53.10
10/26/2015	61.05	1	64.00	66.00	61.40
3/9/2016	62.30	1	69.00	71.00	62.81
7/22/2016	68.86	1	73.00	75.00	68.86

Source: Wells Fargo Securities, LLC estimates and Reuters data


Symbol Key

- ▼ Rating Downgrade
- ▲ Rating Upgrade
- ◆ Valuation Range Change
- ◆ Initiation, Resumption, Drop or Suspend
- Analyst Change
- Split Adjustment

Rating Code Key

- 1 Outperform/Buy
- 2 Market Perform/Hold
- 3 Underperform/Sell
- SR Suspended
- NR Not Rated
- NE No Estimate

Reynolds American Inc. (RAI) 3-yr. Price Performance



Date	Published Price (\$)	Rating Code	Val. Rng. Low	Val. Rng. High	Close Price (\$)
8/6/2013		Herzog			
8/6/2013	NA	2	24.50	25.50	25.45
● 12/3/2013	25.32	2	25.50	26.50	25.10
● 1/23/2014	24.04	2	24.50	25.50	24.52
● 4/29/2014	28.12	2	29.50	30.50	28.12
▲ 5/19/2014	28.67	1	30.00	31.00	28.74
● 6/17/2014	29.99	1	32.00	33.00	29.99
● 10/21/2014	30.52	1	33.50	34.50	30.52
● 11/17/2014	32.35	1	34.50	35.50	32.35
● 1/20/2015	33.79	1	39.50	40.50	34.26
● 4/17/2015	37.35	1	40.50	41.50	37.35
● 5/18/2015	38.18	1	44.50	45.50	38.18
● 7/28/2015	84.20	1	47.00	48.00	42.10
□ 9/1/2015		2-for-1 stock split			
● 9/2/2015	40.94	1	47.00	49.00	41.25
● 10/26/2015	48.89	1	52.00	54.00	49.49
● 12/9/2015	45.42	1	53.00	55.00	45.42
● 7/22/2016	52.29	1	56.00	58.00	52.29

Source: Wells Fargo Securities, LLC estimates and Reuters data


Symbol Key

- ▼ Rating Downgrade
- ▲ Rating Upgrade
- Valuation Range Change
- ◆ Initiation, Resumption, Drop or Suspend
- Analyst Change
- Split Adjustment

Rating Code Key

- 1 Outperform/Buy
- 2 Market Perform/Hold
- 3 Underperform/Sell
- SR Suspended
- NR Not Rated
- NE No Estimate

Philip Morris International Inc. (PM) 3-yr. Price Performance



Date	Published Price (\$)	Rating Code	Val. Rng. Low	Val. Rng. High	Close Price (\$)
8/6/2013		Herzog			
8/6/2013	NA	1	99.00	101.00	88.77
10/17/2013	86.89	1	96.00	98.00	86.89
2/3/2014	78.11	1	94.00	96.00	75.39
6/30/2014	84.85	1	92.00	94.00	84.31
12/18/2014	84.02	1	91.00	93.00	84.02
1/28/2015	80.58	1	88.00	90.00	80.58
3/17/2015	77.89	1	87.00	89.00	77.89
4/16/2015	84.96	1	94.00	96.00	84.96
3/9/2016	94.45	1	109.00	111.00	96.01
7/13/2016	103.24	1	114.00	116.00	103.24

Source: Wells Fargo Securities, LLC estimates and Reuters data

Symbol Key		Rating Code Key	
▼ Rating Downgrade	◆ Initiation, Resumption, Drop or Suspend	1 Outperform/Buy	SR Suspended
▲ Rating Upgrade	■ Analyst Change	2 Market Perform/Hold	NR Not Rated
● Valuation Range Change	□ Split Adjustment	3 Underperform/Sell	NE No Estimate

Additional Information Available Upon Request

I certify that:

- 1) All views expressed in this research report accurately reflect my personal views about any and all of the subject securities or issuers discussed; and
- 2) No part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by me in this research report.

- Wells Fargo Securities, LLC maintains a market in the common stock of Reynolds American Inc., Altria Group, Inc., Philip Morris International Inc.
- Wells Fargo Securities, LLC or its affiliates intends to seek or expects to receive compensation for investment banking services in the next three months from Altria Group, Inc.
- Wells Fargo Securities, LLC or its affiliates received compensation for investment banking services from Reynolds American Inc. in the past 12 months.
- Reynolds American Inc. currently is, or during the 12-month period preceding the date of distribution of the research report was, a client of Wells Fargo Securities, LLC. Wells Fargo Securities, LLC provided investment banking services to Reynolds American

Inc.

- Reynolds American Inc., Altria Group, Inc. currently is, or during the 12-month period preceding the date of distribution of the research report was, a client of Wells Fargo Securities, LLC. Wells Fargo Securities, LLC provided noninvestment banking securities-related services to Reynolds American Inc., Altria Group, Inc.
- Wells Fargo Securities, LLC received compensation for products or services other than investment banking services from Altria Group, Inc., Reynolds American Inc. in the past 12 months.
- Wells Fargo Securities, LLC or its affiliates has a significant financial interest in Reynolds American Inc., Altria Group, Inc., Philip Morris International Inc.

MO: Risks include increased price competition and increased downtrading by consumers.

PM: Risks to our valuation range include currency fluctuations and a broad-based pullback in consumer spending.

RAI: Risks to our valuation include increased competitive pressure within the category and a pullback in consumer spending.

Wells Fargo Securities, LLC does not compensate its research analysts based on specific investment banking transactions. Wells Fargo Securities, LLC's research analysts receive compensation that is based upon and impacted by the overall profitability and revenue of the firm, which includes, but is not limited to investment banking revenue.

STOCK RATING

1=Outperform: The stock appears attractively valued, and we believe the stock's total return will exceed that of the market over the next 12 months. BUY

2=Market Perform: The stock appears appropriately valued, and we believe the stock's total return will be in line with the market over the next 12 months. HOLD

3=Underperform: The stock appears overvalued, and we believe the stock's total return will be below the market over the next 12 months. SELL

SECTOR RATING

O=Overweight: Industry expected to outperform the relevant broad market benchmark over the next 12 months.

M=Market Weight: Industry expected to perform in-line with the relevant broad market benchmark over the next 12 months.

U=Underweight: Industry expected to underperform the relevant broad market benchmark over the next 12 months.

VOLATILITY RATING

V = A stock is defined as volatile if the stock price has fluctuated by +/-20% or greater in at least 8 of the past 24 months or if the analyst expects significant volatility. All IPO stocks are automatically rated volatile within the first 24 months of trading.

As of: August 8, 2016

41% of companies covered by Wells Fargo Securities, LLC Equity Research are rated Outperform.	Wells Fargo Securities, LLC has provided investment banking services for 37% of its Equity Research Outperform-rated companies.
---	---

56% of companies covered by Wells Fargo Securities, LLC Equity Research are rated Market Perform.	Wells Fargo Securities, LLC has provided investment banking services for 27% of its Equity Research Market Perform-rated companies.
---	---

3% of companies covered by Wells Fargo Securities, LLC Equity Research are rated Underperform.	Wells Fargo Securities, LLC has provided investment banking services for 3% of its Equity Research Underperform-rated companies.
--	--

Important Disclosure for International Clients

EEA – The securities and related financial instruments described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. For recipients in the EEA, this report is distributed by Wells Fargo Securities International Limited (“WFSIL”). WFSIL is a U.K. incorporated investment firm authorized and regulated by the Financial Conduct Authority. For the purposes of Section 21 of the UK Financial Services and Markets Act 2000 (“the Act”), the content of this report has been approved by WFSIL a regulated person under the Act. WFSIL does not deal with retail clients as defined in the Markets in Financial Instruments Directive 2007. The FCA rules made under the Financial Services and Markets Act 2000 for the protection of retail clients will therefore not apply, nor will the Financial Services Compensation Scheme be available. This report is not intended for, and should not be relied upon by, retail clients.

Australia – Wells Fargo Securities, LLC is exempt from the requirements to hold an Australian financial services license in respect of the financial services it provides to wholesale clients in Australia. Wells Fargo Securities, LLC is regulated under U.S. laws which differ from Australian laws. Any offer or documentation provided to Australian recipients by Wells Fargo Securities, LLC in the course of providing the financial services will be prepared in accordance with the laws of the United States and not Australian laws.

Good For the Goose, Less For the Gander

Canada – This report is distributed in Canada by Wells Fargo Securities Canada, Ltd., a registered investment dealer in Canada and member of the Investment Industry Regulatory Organization of Canada (IIROC) and Canadian Investor Protection Fund (CIPF). Wells Fargo Securities, LLC’s research analysts may participate in company events such as site visits but are generally prohibited from accepting payment or reimbursement by the subject companies for associated expenses unless pre-authorized by members of Research Management.

Hong Kong – This report is issued and distributed in Hong Kong by Wells Fargo Securities Asia Limited (“WFSAL”), a Hong Kong incorporated investment firm licensed and regulated by the Securities and Futures Commission of Hong Kong (“the SFC”) to carry on types 1, 4, 6 and 9 regulated activities (as defined in the Securities and Futures Ordinance (Cap. 571 of The Laws of Hong Kong), “the SFO”). This report is not intended for, and should not be relied on by, any person other than professional investors (as defined in the SFO). Any securities and related financial instruments described herein are not intended for sale, nor will be sold, to any person other than professional investors (as defined in the SFO). The author or authors of this report is or are not licensed by the SFC. Professional investors who receive this report should direct any queries regarding its contents to Mark Jones at WFSAL (email: wfsalresearch@wellsfargo.com).

Japan – This report is distributed in Japan by Wells Fargo Securities (Japan) Co., Ltd, registered with the Kanto Local Finance Bureau to conduct broking and dealing of type 1 and type 2 financial instruments and agency or intermediary service for entry into investment advisory or discretionary investment contracts. This report is intended for distribution only to professional investors (Tokutei Tousehika) and is not intended for, and should not be relied upon by, ordinary customers (Ippan Tousehika).

The ratings stated on the document are not provided by rating agencies registered with the Financial Services Agency of Japan (JFSA) but by group companies of JFSA-registered rating agencies. These group companies may include Moody’s Investors Services Inc., Standard & Poor’s Rating Services and/or Fitch Ratings. Any decisions to invest in securities or transactions should be made after reviewing policies and methodologies used for assigning credit ratings and assumptions, significance and limitations of the credit ratings stated on the respective rating agencies’ websites.

About Wells Fargo Securities

Wells Fargo Securities is the trade name for the capital markets and investment banking services of Wells Fargo & Company and its subsidiaries, including but not limited to Wells Fargo Securities, LLC, a U.S. broker-dealer registered with the U.S. Securities and Exchange Commission and a member of NYSE, FINRA, NFA and SIPC, Wells Fargo Prime Services, LLC, a member of FINRA, NFA and SIPC, Wells Fargo Securities Canada, Ltd., a member of IIROC and CIPF, Wells Fargo Bank, N.A. and Wells Fargo Securities International Limited, authorized and regulated by the Financial Conduct Authority.

This report is for your information only and is not an offer to sell, or a solicitation of an offer to buy, the securities or instruments named or described in this report. Interested parties are advised to contact the entity with which they deal, or the entity that provided this report to them, if they desire further information. The information in this report has been obtained or derived from sources believed by Wells Fargo Securities, LLC, to be reliable, but Wells Fargo Securities, LLC does not represent that this information is accurate or complete. Any opinions or estimates contained in this report represent the judgment of Wells Fargo Securities, LLC, at this time, and are subject to change without notice. All Wells Fargo Securities research reports published by its Global Research Department (“WFS Research”) are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Additional distribution may be done by sales personnel via email, fax or regular mail. Clients may also receive our research via third party vendors. Not all research content is redistributed to our clients or available to third-party aggregators, nor is WFS Research responsible for the redistribution of our research by third party aggregators. For research or other data available on a particular security, please contact your sales representative or go to <http://www.wellsfargoresearch.com>. For the purposes of the U.K. Financial Conduct Authority’s rules, this report constitutes impartial investment research. Each of Wells Fargo Securities, LLC and Wells Fargo Securities International Limited is a separate legal entity and distinct from affiliated banks. Copyright © 2016 Wells Fargo Securities, LLC

SECURITIES: NOT FDIC-INSURED/NOT BANK-GUARANTEED/MAY LOSE VALUE